GE Healthcare Launches Cytiva Plus Cardiomyocytes - - BioPharm International

ADVERTISEMENT

GE Healthcare Launches Cytiva Plus Cardiomyocytes


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

GE Healthcare introduces the Cytiva Plus, a high fidelity human heart cell model that is available in quantities compatible with screening for cardiotoxicity, enabling earlier and more confident prioritization of compounds.

The Cytiva Plus is cryopreserved in quantities to match a range of applications, which are ready-for-use in multi-electrode arrays, impedance, and high content analysis applications for compound safety profiling.

The cardiomyocytes are produced in a way that reflects native human heart cell development, without engineering techniques that could alter expression levels of relevant genes. This makes Cytiva Plus a reproducible biologically relevant cell model that supports the measurement of electrophysiological, structural and functional cell changes, and demonstrates expected pharmacological responses to reference compounds, the company reports.

Cytiva Plus is compatible with various detection platforms, enabling compound profiling based on multiple cardiotoxicity indications for more integrated risk assessment and mechanistic investigations.

Source: GE Healthcare

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here